Dizziness · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy
Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
Time to next exacerbation · adults and children with CF
1 finding from 1 review
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Erectile dysfunction · erectile dysfunction in men with obstructive sleep apnoea
2 findings from 1 review
Health‐related quality of life · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review
Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Erectile dysfunction · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review
Serious adverse events · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review
Sex‐related quality of life (QoL) · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review
Health‐related quality of life · erectile dysfunction in men with obstructive sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea
It is very uncertain whether continuous positive airway pressure (CPAP) changes minor adverse events compared with phosphodiesterase type 5 inhibitors (very low certainty).
1 finding from 1 review
Serious adverse events · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review
Sex‐related quality of life (QoL) · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review